scholarly journals Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients

2014 ◽  
Vol 27 (6) ◽  
pp. 1106-1116 ◽  
Author(s):  
Swetlana Mactier ◽  
Kimberley L. Kaufman ◽  
Penghao Wang ◽  
Ben Crossett ◽  
Gulietta M. Pupo ◽  
...  
Keyword(s):  
Stage Iii ◽  
Survival Outcomes ◽  
Ajcc Stage ◽  
Protein Signatures ◽  
Melanoma Patients ◽  
Stage Iii Melanoma

PP 3 S-100B concentrations predict disease specific survival in AJCC Stage III melanoma patients

2011 ◽  
Vol 47 ◽  
pp. S21
Author(s):  
S. Kruijff ◽  
E. Bastiaannet ◽  
M. Speijers ◽  
I. Kema ◽  
R. van Ginkel ◽  
...  
Keyword(s):  
Stage Iii ◽  
Disease Specific Survival ◽  
Ajcc Stage ◽  
Melanoma Patients ◽  
Stage Iii Melanoma ◽  
Disease Specific

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.

1994 ◽  
Vol 12 (5) ◽  
pp. 1036-1044 ◽  
Author(s):  
P O Livingston ◽  
G Y Wong ◽  
S Adluri ◽  
Y Tao ◽  
M Padavan ◽  
...  
Keyword(s):  
Overall Survival ◽  
Stage Iii ◽  
Disease Free Interval ◽  
Free Interval ◽  
Ajcc Stage ◽  
Melanoma Patients ◽  
Stage Iii Melanoma ◽  
Receive Treatment ◽  
To Receive ◽  
Disease Free

PURPOSE To perform a double-blind randomized trial with American Joint Commission on Cancer (AJCC) stage III melanoma patients for the following reasons: (1) to confirm our previous finding that patients with antibodies against the melanoma differentiation antigen GM2 have an improved prognosis, and (2) to demonstrate clinical benefit from GM2 antibody induction. PATIENTS AND METHODS One hundred twenty-two patients with AJCC stage III melanoma who were free of disease after surgery were randomized: 58 to receive treatment with the GM2/BCG vaccine, and 64 to receive treatment with bacille Calmette-Guèrin (BCG) alone. All patients were pretreated with low-dose cyclophosphamide (Cy). RESULTS GM2 antibody was detected in 50 of 58 patients treated with GM2/BCG and seven of 64 patients treated with BCG alone. With a minimum follow-up period of 51 months, there was a highly significant increase in the disease-free interval (P = .004) and a 17% increase in overall survival (P = .02) in these 57 antibody-positive patients, confirming our earlier experience. Exclusion of all patients with preexisting GM2 antibodies (one in the GM2/BCG group and five in the BCG group) from statistical analysis resulted in a 23% increase in disease-free interval (P = .02) and a 14% increase in overall survival (P = .15) at 51 months for patients treated with the GM2/BCG vaccine. However, when all patients in the two treatment groups were compared as randomized, these increases were 18% for disease-free interval and 11% for survival in the GM2/BCG treatment group, with neither result showing statistical significance. CONCLUSION (1) Vaccination with GM2/BCG induced immunoglobulin M (IgM) antibodies in most patients. (2) GM2 antibody production was associated with a prolonged disease-free interval and survival. (3) Comparison of the two arms of this trial as randomized fails to show a statistically significant improvement in disease-free interval or survival for patients treated with GM2/BCG vaccines.

S-100B as a selection tool for FDG-PET-CT scanning to detect recurrent disease in AJCC stage III melanoma patients

2019 ◽  
Vol 45 (2) ◽  
pp. e134-e135
Author(s):  
E. Deckers ◽  
K. Wevers ◽  
L. Been ◽  
B. van Leeuwen ◽  
R. van Ginkel ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Recurrent Disease ◽  
Ct Scanning ◽  
Stage Iii ◽  
Selection Tool ◽  
Ajcc Stage ◽  
Pet Ct ◽  
Melanoma Patients ◽  
Stage Iii Melanoma ◽  
Fdg Pet Ct

scholarly journals Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients

2014 ◽  
Vol 31 (4) ◽  
pp. 407-421 ◽  
Author(s):  
Kimberley L. Kaufman ◽  
Swetlana Mactier ◽  
Nicola J. Armstrong ◽  
Duthika Mallawaaratchy ◽  
Scott N. Byrne ◽  
...  
Keyword(s):  
Lymph Node ◽  
Surface Antigen ◽  
Lymph Node Metastases ◽  
Melanoma Cells ◽  
Stage Iii ◽  
Ajcc Stage ◽  
Node Metastases ◽  
Melanoma Patients ◽  
Stage Iii Melanoma

scholarly journals S‐100B as an extra selection tool for FDG PET/CT scanning in follow‐up of AJCC stage III melanoma patients

2019 ◽  
Vol 120 (6) ◽  
pp. 1031-1037 ◽  
Author(s):  
Eric A. Deckers ◽  
Kevin P. Wevers ◽  
Anneke C. Muller Kobold ◽  
Samantha Damude ◽  
Otis M. Vrielink ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Ct Scanning ◽  
Stage Iii ◽  
Selection Tool ◽  
Ajcc Stage ◽  
Pet Ct ◽  
Melanoma Patients ◽  
Stage Iii Melanoma ◽  
Fdg Pet Ct

Molecular Tumor Markers in the Blood: Early Prediction of Disease Outcome in Melanoma Patients Treated With a Melanoma Vaccine

2003 ◽  
Vol 21 (13) ◽  
pp. 2558-2563 ◽  
Author(s):  
Robert A. Wascher ◽  
Donald L. Morton ◽  
Christine Kuo ◽  
Robert M. Elashoff ◽  
He-Jing Wang ◽  
...  
Keyword(s):  
Phase Ii ◽  
Disease Recurrence ◽  
Stage Iii ◽  
Rt Pcr ◽  
Melanoma Vaccine ◽  
Blood Assay ◽  
Ajcc Stage ◽  
Melanoma Patients ◽  
Stage Iii Melanoma ◽  
Disease Free

Purpose: Patients with American Joint Committee on Cancer (AJCC) stage III melanoma are at high risk of recurrence and death. We hypothesized that a multiple-marker reverse transcriptase polymerase chain reaction (MM-RT-PCR) blood assay could predict, early in the course of therapy, those patients destined to experience treatment failure with a melanoma vaccine (MV) previously shown to improve survival in a phase II clinical trial.Patients and Methods: After complete surgical resection, prospectively collected cryopreserved peripheral-blood lymphocyte specimens (n = 90) from the serial bleeds of 30 patients with AJCC stage III melanoma were studied by MM-RT-PCR, using the markers tyrosinase, melanoma antigen recognized by T cells-1 (MART-1), and universal melanoma antigen gene-A (uMAG-A). All patients were enrolled in a phase II MV trial during the period of blood draws, and were selected for this study in a blinded fashion. Median duration of clinical follow-up was 74 months for the 13 survivors and 11 months for the 17 nonsurvivors.Results: The presence of at least one melanoma-specific RT-PCR marker was associated with an increased risk of disease recurrence (risk rate, 3.12; P = .02) and decreased risk of survival (relative rate, 2.62; P = .0496) by multivariate analysis.Conclusion: MM-RT-PCR of the blood provided early prediction of subsequent disease recurrence and death in clinically disease-free AJCC stage III melanoma patients enrolled in a MV phase II trial. On the basis of the results of this pilot study, the MM-RT-PCR blood assay should be considered as a clinically important monitoring tool for assessing patient response to adjuvant therapy, and in the surveillance of clinically disease-free patients for the earliest signs of recurrence.

Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients

2002 ◽  
Vol 51 (10) ◽  
pp. 532-538 ◽  
Author(s):  
Nathalie Labarrière ◽  
Marie-Christine Pandolfino ◽  
Nadine Gervois ◽  
Amir Khammari ◽  
Marie-Hélène Tessier ◽  
...  
Keyword(s):  
Therapeutic Efficacy ◽  
Stage Iii ◽  
Melanoma Patients ◽  
Stage Iii Melanoma

Predicting clinical outcome through gene expression profiling in stage III melanoma

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 8502-8502
Author(s):  
T. John ◽  
M. A. Black ◽  
T. Toro ◽  
C. A. Gedye ◽  
I. D. Davis ◽  
...  
Keyword(s):  
Gene Expression ◽  
Clinical Outcome ◽  
Gene Expression Profiling ◽  
Expression Profiling ◽  
Stage Iiib ◽  
Stage Iii ◽  
Test Set ◽  
Prognostic Groups ◽  
Melanoma Patients ◽  
Stage Iii Melanoma

8502 Background: Melanoma patients with clinically involved regional lymph nodes (Stage IIIB&C) represent a prognostically heterogeneous population. Current prognostic factors cannot distinguish the 30% of patients who will achieve long term survival from those who will relapse early. We hypothesized that gene expression profiling could identify these different prognostic groups and provide a greater understanding of the genetic mechanisms involved. Methods: Lymph node sections from 29 patients with Stage IIIB & IIIC melanoma and divergent clinical outcome as defined by time to tumor progression (TTP), including 16 poor (TTP<6 months) and 13 good (TTP>28 months) prognosis patients, were subjected to molecular profiling using spotted oligonucleotide arrays containing 30,888 probes as an initial test set. The differentially expressed genes were determined using a Wilcoxon-Mann-Whitney t-test with the false discovery rate controlling method of Benjamini-Hochberg and validated using quantitative real-time RT-PCR. Using logistic regression, a predictive score algorithm was developed based on the 15 genes for which the correlation between the two platforms was the strongest. The score was then applied to two independent validation sets of 10 and 14 patient samples. Results: Supervised analysis using differentially expressed genes was able to distinguish the two prognostic groups in the test set. The score correlated directly with clinical outcome, with higher scores associated with improved TTP. When the score was then applied to two independent sets of Stage III melanoma patient samples, it predicted clinical outcome accurately in 90% of samples. Conclusions: Stage IIIB and IIIC melanoma can be prognostically sub-classified according to the expression of 15 genes. To our knowledge this is the first study focused on Stage III disease using ex vivo patient samples. These results are encouraging and this genetic signature is currently being validated on a larger cohort. This method will allow appropriate stratification of stage III melanoma patients in adjuvant clinical trials, ameliorating the inherent biological heterogeneity that can confound these studies. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document